Suppr超能文献

IgY 技术的产业化和商业化趋势。

Trends in industrialization and commercialization of IgY technology.

机构信息

College of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong, Shaanxi, China.

Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.

出版信息

Front Immunol. 2022 Oct 20;13:991931. doi: 10.3389/fimmu.2022.991931. eCollection 2022.

Abstract

IgY technology refers to the strategic production process involved in generating avian immunoglobulin (IgY) against target antigens in a much more cost-effective manner with broad applications in the fields of diagnostics, prophylaxis, and therapeutics for both human and veterinary medicine. Over the past decade, promising progress in this research area has been evident from the steep increase in the number of registered manufacturing companies involved in the production of IgY products, the number of patents, and the notable number of clinical trials underway. Hence, it is crucial to conduct a prospective analysis of the commercialization and marketing potential of IgY-based commercial products for large-scale applications. This review revealed that the number of IgY patent applications increased steeply after 2010, with the highest of 77 patents filed in 2021. In addition, 73 industries are reportedly involved in marketing IgY products, out of which 27 were promoting biotherapeutics for human and veterinary medicine and 46 were in the diagnostic field. IgY antibodies are being used as primary and secondary antibodies, with approximately 3729 and 846 products, respectively. Biotherapeutic product consumption has notably increased as a food supplement and as a topical application in human and veterinary medicine, which are under different clinical phases of development to reach the market with around 80 and 56 products, respectively. In contrast, the number of IgY products as parenteral administrations and licensed drugs is not well developed given the lack of technical standards established for IgY registration and industrialization, as well as the restriction of the nature of polyclonal antibodies. However, recent ongoing research on functional IgY fragments indicates a promising area for IgY applications in the near future. Therefore, retrospective analysis with speculations is mandatory for IgY technology maturation toward industrialization and commercialization.

摘要

IgY 技术是指通过更具成本效益的方式针对目标抗原产生禽类免疫球蛋白 (IgY) 的战略生产工艺,广泛应用于人类和兽医医学的诊断、预防和治疗领域。在过去的十年中,从参与 IgY 产品生产的注册制造公司数量、专利数量以及正在进行的临床试验数量的显著增加可以明显看出该研究领域的可喜进展。因此,对基于 IgY 的商业产品的商业化和营销潜力进行前瞻性分析至关重要。本综述表明,2010 年后 IgY 专利申请数量急剧增加,2021 年申请数量最高,达 77 项。此外,据报道,有 73 个行业参与营销 IgY 产品,其中 27 个行业用于推广人类和兽医医学的生物疗法,46 个行业用于诊断领域。IgY 抗体被用作一抗和二抗,分别约有 3729 种和 846 种产品。生物治疗产品的消费显著增加,作为人类和兽医医学的食品补充剂和局部应用,处于不同的临床开发阶段,分别有 80 种和 56 种产品有望推向市场。相比之下,由于缺乏为 IgY 注册和产业化制定的技术标准,以及多克隆抗体性质的限制,作为注射剂和许可药物的 IgY 产品数量并未得到很好的发展。然而,最近对功能性 IgY 片段的研究表明,IgY 在不久的将来在应用方面有很大的发展前景。因此,为了实现 IgY 技术向产业化和商业化的成熟,对其进行回顾性分析和推测是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9749/9630564/19d71eae9e83/fimmu-13-991931-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验